

Fig. 1




Fig. 4




Fig. 5




Fig. 9

BEST AVAILABLE COPY





Fig. 10

BEST AVAILABLE COPY

**β ivalent Anti- PSM6FR Stimulates Cell Growth in
MUC1⁺ Breast Tumor Cells - 1504**



BEST AVAILABLE COPY

Fig. 21

BESI Approved COPY

**Anti- β Sm6F α Stimulates Growth of Breast Tumor
Cell Line 1500**

**1500 cells (6000 per well) stimulated with anti- β Sm6F α and
Harvested at 3 days**




Fig. 22

NOT AVAILABLE COPY

Anti-*PSMGFR* Stimulates Growth of Breast Tumor Cell Line 1500

1500 cells stimulated every 24h or 48h with anti-*PSMGFR* and harvested at 2 days (red), 3 days (yellow), or 4 days (blue)




Fig. 23

Bivalent Anti- α PSM6FR Stimulates Cell Proliferation in T47D Cells

The Effect of α PSM6FR Bivalent Antibody on T47D cell Proliferation




Fig. 29

β ivalent Anti- β _{SM6F2} Stimulates Cell Proliferation in BT-474 Cells




Fig. 25

Monovalent Anti- β SM6Fc Inhibits Growth of Breast Tumor Cell Line 1504




Fig. 27

Monovalent Anti- $P_{S\beta M6FR}$ Inhibits Growth of Breast Tumor Cell Line 1500

Effect of Monovalent Anti- $P_{S\beta M6FR}$ (24hr Interval) on 1500 cell proliferation - Harvested after 7 days




Fig. 20

Monovalent Competes with Bivalent Anti-*PSM6FL* and Blocks Color Change in Nanoparticle Assay




Fig. 29

**Breast Tumor Cells Produce MUC1 Cleavage
Products of Apparent Molecular Weight 20 – 30 kDa**




Fig. 30

**Anti- β SMGFR α Dimerizes MUC1 in T47D Cells and
Activates Intracellular MAP Kinase Cell Proliferation
Pathway**




Fig. 31

Bivalent Anti- β -Synergin Induces MAP Kinase Cell Proliferation Pathway in 1504 Breast Tumor Cells

Time-Course effect of Anti- β -Synergin* (5ul) on ERK2 Pathway in 1504 Cell line




Fig. 32

**β ivalent Anti-*PSN6F2* Also Induces ERK2
Phosphorylation in 1500 Breast Tumor Cells**

**Time-Course effect of Anti-*PSN6F2* (5ul) on ERK2 Pathway in
1500 Cell line**




Fig. 33

MN Compounds Compete with Antibody to Bind to $PSM6FR$ & Block Activation of MAP Kinase Proliferation Pathway




Fig. 34

BEST AVAILABLE COPY

Monovalent Inhibits ERK2 Phosphorylation

Anti-~~PSM 442~~ (5uI) and Monovalent (10uI) Antibody effect on ERK2 Pathway in 1500 Cell line




Fig. 35

BEST AVAILABLE COPY

Breast Tumor Cells Present Full-Length as well as Cleaved MUC1





Fig. 36

BEST AVAILABLE COPY

BEST AVAILABLE COPY


MUC1 Cleavage Products are N-Glycosylated

BEST AVAILABLE COPY




MUC1 Variants Transfected into HEK Cells

BEST AVAILABLE COPY



F16.38



Tumor-Specific ~20 kDa Band




Fig. 39

Monovalent Anti- β PSM6FR Inhibits Cell Growth in

α PSM6FR⁺ Transfectants

PCT/US2004/027954

24/28

WO 2005/019269




Fig. 40

Anti-*PSM6FL* (5uI) Antibody Induces ERK2 Phosphorylation in HEK Cells Transfected with

Mad-PSM6FL




FIG. 41

not-PSA6PK **In Transfectants β ivalent (5ul) Activates ERK2 - Monovalent (10ul) Inhibits**




FIG. 42




FIG. 13

NOT AVAILABLE COPY

Breast Tumor Cells May Produce Two Cleavage Products




Fig. 44